Company Overview: ONCOSEC

Industry News

12 Oct

OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

Additional abstract highlighting preclinical data from OncoSec’s novel multi-gene expression platform SAN DIEGO, Oct. 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated clinical data from its phase 2 Investigator Sponsored Trial assessing the combination of OncoSec’s investigational therapy, ImmunoPulse® IL-12 (intratumoral...

Read more

12 Oct

OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research

OncoSec presented at the 2nd Annual Biomarkers & Precision Medicine USA Congress SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12 with electroporation), its lead program focused...

Read more

10 Oct

OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck’s KEYTRUDA® (pembrolizumab)

Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy Global study in the U.S. and Australia ImmunoPulse® IL-12 granted Fast Track and Orphan Drug Designation in the U.S. SAN DIEGO, Oct. 10, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company...

Read more

27 Sep

OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of “Cold” Tumors to “Hot” Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy

SAN DIEGO, Sept. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented an overview of the comprehensive immune monitoring data from the Phase 2 Investigator Sponsored Trial led by the University of California, San Francisco(UCSF) at the 2nd World Congress on Electroporation and Pulsed Electric...

Read more

7 Sep

OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors

Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems adds significant biopharma clinical, regulatory, business development, and fundraising expertise to OncoSec SAN DIEGO, Sept. 7, 2017 /PRNewswire/ — OncoSec Medical Incorporated “OncoSec” (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O’Connor to...

Read more

5 Sep

OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors

Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec SAN DIEGO, Sept. 5, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company” (ONCS)), a company developing DNA-based intratumoral cancer...

Read more

12 Jun

OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.

SAN DIEGO, June 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that they have engaged in a preclinical agreement through the OncoSec Technology Access Program (TAP) with Jounce Therapeutics, Inc., (JNCE) Cambridge, MA, a company focused on the discovery...

Read more

2 Jun

OncoSec to Present at LD Micro Invitational

SAN DIEGO, June 2, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will be featured as a presenting company at the upcoming LD Micro Invitational to be held on June 6-7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Punit...

Read more

1 Jun

OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017

SAN DIEGO, June 1, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced third quarter and year-to-date financial results ended April 30, 2017. “We have made significant progress this past quarter in advancing our clinical and regulatory pathway for ImmunoPulse® IL-12, which...

Read more

11 May

OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

SAN DIEGO, May 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal third quarter 2017 financial results conference call on Thursday, June 1 at 1:15 PM PT/4:15 PM ET. To access the audio...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address